Irvine, CA - A court injunction preventing the sale of Medtronic's CoreValve in Germany went into effect yesterday, the manufacturer of the CoreValve's chief competitor, Edwards Lifesciences, ...
Siegburg, Germany - Percutaneous implantation of the self-expanding CoreValve aortic valve bioprosthesis in the first-ever series of patients shows that the procedure is feasible in those deemed too ...
Leading medical device major Medtronic Inc.'s (MDT) self-expanding CoreValve transcatheter aortic valve system recently exhibited cost efficiency in transcatheter aortic valve replacement (:TAVR) ...
Medtronic's CoreValve system today gained a second indication from the FDA for use in patients with severe aortic stenosis who are at high risk for surgery. The transcatheter aortic valve replacement ...
The approval is based on the positive results depicted by the High Risk study of the CoreValve U.S. Pivotal Trial, where the CoreValve System has shown superior clinical outcomes compared to ...
The FDA today approved Medtronic's CoreValve transcatheter aortic valve replacement (TAVR) system for patients with severe aortic stenosis who are unable to undergo conventional open-heart surgery.
Meta-Analysis of Seven International Clinical Registries Presented at EuroPCR 2011 Late-Breaking Presentation PARIS – A late-breaking presentation about transcatheter aortic valve implantation (TAVI) ...
Add Yahoo as a preferred source to see more of our stories on Google. NEW YORK (AP) -- Medtronic said Monday that a federal appeals court has ruled it can continue selling its CoreValve heart valve ...
Medtronic Inc. announced Tuesday that its CoreValve System, designed to enable the replacement of a diseased aortic valve without open heart surgery, showed health improvements over a two-year period ...
Leading medical devices player, Medtronic (NYSE:MDT - News) has taken one step forward in its CoreValve US pivotal trial with completion of enrollment in the extreme risk category of patients. The ...
Medtronic, Inc. 's ( MDT) CoreValve transcatheter aortic valve replacement (TAVR) system continues to provide efficient treatment at two years for extreme-risk patients, the company announced at the ...
Approximately 1 in 3 patients with severe aortic stenosis who undergo transcatheter aortic valve implantation (TAVI) with the CoreValve device will require a permanent pacemaker within 30 days of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results